Specialty Connect

(Specialty Connect) Specialty Connect: A Focus on Immune-Mediated Skin Conditions

Tuesday, October 11, 2022

1:00 PM – 5:30 PM ET

Location: Maryland 5/6

ACPE UAN:0233-0000-22-031-L01-P | Contact Hours: 4 | Activity Type: Knowledge-based

Faculty(s)

Casey Butrus, PharmD

Senior Pharmacist
Highmark
Pittsburgh, PA
Stephanie Cho, PharmD, BCPS

Clinical Pharmacy Specialist in Dermatology
Kaiser Permanente Colorado
Lone Tree, CO
Noelia Ferreyra

Patient Advocate
National Psoriasis Foundation
La Mesa, CA
Cheri Frey, MD

Asst Professor, Program Director
Howard University
Washington, DC
Leah M. Howard, JD

President & CEO
National Psoriasis Foundation
Alexandria, VA
Steven S. Kheloussi, PharmD, MBA

Manager, Clinical Pharmacy
Highmark Inc.
Wilkes Barre, PA
Clive Liu, MD

Director
Bellevue Dermatology
Bellevue, WA

Moderator(s)

Eleanor M. Perfetto, PhD, MS

Professor
University of Maryland Baltimore, School of Pharmacy, Department of Pharmaceutical Health Services Research
Baltimore, Maryland

This activity is supported by independent educational grants from Incyte Corporation, Sanofi and Regeneron Pharmaceuticals, Novartis Pharmaceuticals Corporation, Pfizer Inc., and Boehringer Ingelheim Pharmaceuticals Inc.

Note: Registration for Specialty Connect is separate from the AMCP Nexus 2022 meeting. Registration Fees: $195 AMCP Members; $225 Non-Members.

Multiple skin conditions — including psoriasis, atopic dermatitis, and alopecia areata — are mediated by complex immunological pathways that drive disease onset and progression. Recent years have seen the introduction of novel targeted therapies inhibit cytokines that play key roles in these pathways, and many more related therapies are in development. Targeted immune-modulating therapies offer patients with moderate to severe disease additional opportunities to achieve and maintain disease control. However, the rapidly growing therapeutic armamentarium presents challenges for managed care professionals seeking to develop and implement evidence-based, patient-centered policies to ensure that the right patient has access to the right therapy at the right time. During Specialty Connect, experts will focus on managed care considerations for managing immune-mediated skin conditions. Topics will include the future pipeline, considerations for treatment selection, and formulary and financial risk management strategies.

Specialty Connect is a strategic, forward-thinking pre-conference program designed to focus on topics important to those involved with specialty management. The program is designed for and with industry leaders, experts, and managed care professionals operating in this fast-growing sector and will provide opportunities to both learn and network with those interested in specialty management.

Agenda
1:00 – 1:05 pm Welcome and Introductions
1:05 – 2:05 pm Overview of the Natural History and Burden of Immune-Mediated Skin Conditions
2:05 – 2:50 pm New and Emerging Targeted Therapies for Immune-Mediated Skin Conditions
2:50 – 3:10 pm Break
3:10 – 4:00 pm Evidence-Based and Patient-Specific Considerations for Optimizing Treatment Outcomes
4:00 – 4:30 pm Payer Perspectives on Treatment Decision-Making and Access
4:30 – 5:25 pm Panel Discussion
5:25 – 5:30 pm Closing

Learning Objectives:

At the completion of this activity, participants should be able to:

Describe impact of moderate-to-severe immune-mediated skin conditions on clinical and patient-reported outcomes, healthcare utilization, and costs.
Differentiate new and emerging targeted therapies for immune-mediated skin conditions based on mechanisms of action, efficacy and safety data, and indications.
Discuss guidelines, clinical data, and patient factors to treatment decision-making for diverse patients with immune-mediated skin conditions.
Identify formulary designs, contracting, and other financial risk management strategies for the treatment of immune-mediated skin conditions.